Maria C. Freire
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Exelixis Shares Rise on CABOMETYX Revenue. Exelixis stock has moved higher following reports of strong revenue from its drug CABOMETYX. This performance is relevant as it demonstrates the commercial strength of the company's primary product. The FDA also expanded the label for Merck's Welireg, a competitor in the kidney cancer space, which adds context to the market environment.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
ARE Finalizes $5 Billion Credit Facility Refinancing. Alexandria Real Estate Equities has closed its amended $5 billion unsecured senior line of credit. This move comes as the stock faces broader pressure from rising interest rates, with the share price currently near key support levels. The refinancing provides the company with updated liquidity options in a challenging rate environment.
Transaction History
| BIIB | ▲ Buy | Grant | 2,005 | $0 | 6/9/2026 | View on chart |
| EXEL | ▲ Buy | Grant | 8,367 | $0 | 5/27/2026 | View on chart |
| EXEL | ▲ Buy | Option Exercise | 20,634 | $408K | 5/7/2026 | View on chart |
| EXEL | ▼ Sell | Open Market | 20,634 | $949K | 5/7/2026 | View on chart |
| ARE | ▲ Buy | Grant | 3,493 | $0 | 1/15/2026 | View on chart |
| BIIB | ▲ Buy | Grant | 2,370 | $0 | 6/17/2025 | View on chart |
| EXEL | ▲ Buy | Grant | 9,812 | $0 | 5/29/2025 | View on chart |
| EXEL | ▲ Buy | Option Exercise | 15,874 | $325K | 2/14/2025 | View on chart |
| EXEL | ▲ Buy | Option Exercise | 28,240 | $624K | 2/14/2025 | View on chart |
| EXEL | ▼ Sell | Open Market | 44,114 | $1.5M | 2/14/2025 | View on chart |
| ARE | ▲ Buy | Grant | 2,032 | $0 | 1/15/2025 | View on chart |
| EXEL | ▼ Sell | Open Market | 8,250 | $219K | 8/14/2024 | View on chart |
| BIIB | ▲ Buy | Grant | 1,340 | $0 | 6/21/2024 | View on chart |
| EXEL | ▲ Buy | Grant | 18,838 | $0 | 5/31/2024 | View on chart |
| ARE | ▲ Buy | Grant | 1,585 | $0 | 1/12/2024 | View on chart |
| BIIB | ▲ Buy | Grant | 960 | $0 | 6/26/2023 | View on chart |
| EXEL | ▲ Buy | Grant | 20,718 | $0 | 6/1/2023 | View on chart |
| ARE | ▲ Buy | Grant | 1,125 | $0 | 1/13/2023 | View on chart |
| ARE | ▼ Sell | Open Market | 289 | $48K | 7/29/2022 | View on chart |
| ARE | ▼ Sell | Open Market | 2,311 | $377K | 7/28/2022 | View on chart |
| BIIB | ▲ Buy | Grant | 1,370 | $0 | 6/15/2022 | View on chart |
| EXEL | ▲ Buy | Grant | 19,575 | $0 | 5/26/2022 | View on chart |
| ARE | ▲ Buy | Grant | 738 | $0 | 1/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Biogen sees kidney therapy progress and rating upgrade
Biogen is receiving attention after a kidney transplant milestone was reported, highlighting its involvement in kidney disease research. The company’s partner Estuary Therapeutics raised $93 million to advance a gene‑therapy for kidney disease, adding to the pipeline focus. Analysts have upgraded Biogen’s outlook, noting growth potential beyond its Alzheimer’s products. An earnings preview also points to upcoming results that could shape market views.
Biogen sees kidney therapy progress and rating upgrade. Biogen is receiving attention after a kidney transplant milestone was reported, highlighting its involvement in kidney disease research. The company’s partner Estuary Therapeutics raised $93 million to advance a gene‑therapy for kidney disease, adding to the pipeline focus. Analysts have upgraded Biogen’s outlook, noting growth potential beyond its Alzheimer’s products. An earnings preview also points to upcoming results that could shape market views.